Cart
sales@molnova.com
SXC 2023
CAS No. 1695562-36-7
SXC 2023( —— )
Catalog No. M36974 CAS No. 1695562-36-7
SXC 2023 ((S)-2-acetamido-3-(4-methylbenzoylthio)propanoic acid) is a therapeutic prodrug of N-acetyl-L-cysteine for the treatment of CNS disorders and neurocognitive disorders, and can be used to treat glutamatergic dysfunction and psychiatric disorders in which oxidative stress plays a key role.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 37 | Get Quote |
|
| 10MG | 54 | Get Quote |
|
| 25MG | 86 | Get Quote |
|
| 50MG | 139 | Get Quote |
|
| 100MG | 228 | Get Quote |
|
| 500MG | 569 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSXC 2023
-
NoteResearch use only, not for human use.
-
Brief DescriptionSXC 2023 ((S)-2-acetamido-3-(4-methylbenzoylthio)propanoic acid) is a therapeutic prodrug of N-acetyl-L-cysteine for the treatment of CNS disorders and neurocognitive disorders, and can be used to treat glutamatergic dysfunction and psychiatric disorders in which oxidative stress plays a key role.
-
DescriptionSXC 2023 ((S)-2-acetamido-3-(4-methylbenzoylthio)propanoic acid) is a therapeutic prodrug of N-acetyl-L-cysteine for the treatment of CNS disorders and neurocognitive disorders, and can be used to treat glutamatergic dysfunction and psychiatric disorders in which oxidative stress plays a key role.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1695562-36-7
-
Formula Weight281.33
-
Molecular FormulaC13H15NO4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(SC[C@H](NC(C)=O)C(O)=O)(=O)C1=CC=C(C)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
PHM-27/PHI, human
PHM-27/PHI, human
-
Vazegepant HCl
Vazegepant is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.
-
Revdofilimab
Revdofilimab (ABBV-368) is a human IgG1 monoclonal antibody that acts as an agonist against OX40, a TNF receptor superfamily member expressed on activated and memory T cell subsets as well as T regulatory cells .
